Glial tumors treatment at the current stage of development

Glial tumors have been and continue to be the most frequent tumors found in neurosurgeon practice. Each year, thousands of publications complement doctors’ insights into the tactics and methods of their treatment. Given the rapidly growing body of information on the subject, the development of common approaches to the problem is an important contribution to the work of a medical practitioner. In the framework of the VII Annual Conference of Neurosurgeons of the North-West Federal District in 2020 leading specialists in the field of glial tumors treatment recorded uniform and relevant approaches. It based on the latest scientific evidence and personal experience for specialists of different profiles.

1. Bailey P., Cushing H. Medulloblastoma cerebella ArchIives of Neurology and Psychiatry. 1925(14):192–224.

2. Claus E.B., Black P.M. Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973–2001. Cancer. 2006;106(6):1358–63.

3. McGirt M.J. Chaichana K.L., Attenello F.J., Weingart J.D., Than K., Burger P.C., et al. Extent of surgical resection is independently associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery. 2008;63(4):700–7; author reply 7–8.

4. John F., Robinette N.L., Amit-Yousif A.J., Bosnyák E., Barger G.R., Shah K.D., et al. Multimodal Imaging of Nonenhancing Glioblastoma Regions. Molecular imaging. 2019;18:1536012119885222.

5. Law I., Albert N.L., Arbizu J., Boellaard R., Drzezga A., Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18) F]FDG: version 1.0. European journal of nuclear medicine and molecular imaging. 2019;46(3):540–57.

6. Lescher S., Schniewindt S., Jurcoane A., Senft C., Hattingen E. Time window for postoperative reactive enhancement after resection of brain tumors: less than 72 hours. Neurosurgical focus. 2014;37(6): E3.

7. Wen P.Y., Macdonald D.R., Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(11):1963–72.

8. Thust S.C., van den Bent M.J., Smits M. Pseudoprogression of brain tumors. Journal of magnetic resonance imaging: JMRI. 2018;48(3):571– 89.

9. Kim M.M., Umemura Y., Leung D. Bevacizumab and Glioblastoma: Past, Present, and Future Directions. Cancer journal (Sudbury, Mass). 2018;24(4):180–6.

10. National Guideline A. National Institute for Health and Care Excellence: Clinical Guidelines. Brain tumours (primary) and brain metastases in adults. London: National Institute for Health and Care Excellence (UK) Copyright © NICE2018.; 2018.

11. Liu Y., Yang M., Luo J., Zhou H. Radiotherapy targeting cancer stem cells «awakens» them to induce tumour relapse and metastasis in oral cancer. International journal of oral science. 2020;12(1):19.

12. Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-oncology. 2001;3(3):193–200.

13. Capelle L., Fontaine D., Mandonnet E., Taillandier L., Golmard J.L., Bauchet L., et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery. 2013;118(6):1157–68.

14. Durmaz R., Vural M., Işildi E., Coşan E., Ozkara E., Bal C., et al. Efficacy of prognostic factors on survival in patients with low grade glioma. Turkish neurosurgery. 2008;18(4):336–44.

15. Kiliç T., Ozduman K., Elmaci I., Sav A., Necmettin Pamir M. Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia. 2002;9(5):549–52.

16. Peraud A., Ansari H., Bise K., Reulen H.J. Clinical outcome of supratentorial astrocytoma WHO grade II. Acta neurochirurgica. 1998;140(12):1213–22.

17. Sanai N., Polley M.Y., Berger M.S. Insular glioma resection: assessment of patient morbidity, survival, and tumor progression. Journal of neurosurgery. 2010;112(1):1–9.

18. Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta neuropathologica. 2016;131(6):803–20.

19. Molinaro A.M., Hervey-Jumper S., Morshed R.A., Young J., Han S.J., Chunduru P., et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA oncology. 2020;6(4):495–503.

20. Watts C., Sanai N. Surgical approaches for the gliomas. Handbook of clinical neurology. 2016;134:51–69.

21. Duffau H. Diffuse low-grade gliomas and neuroplasticity. Diagnostic and interventional imaging. 2014;95(10):945–55.

22. Sawaya R., Hammoud M., Schoppa D., Hess K.R., Wu S.Z., Shi W.M., et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery. 1998;42(5):1044–55; discussion 55–6.

23. Yang K., Nath S., Koziarz A., Badhiwala J.H., Ghayur H., Sourour M., et al. Biopsy Versus Subtotal Versus Gross Total Resection in Patients with Low-Grade Glioma: A Systematic Review and Meta-Analysis. World neurosurgery. 2018;120: e762-e75.

24. Jakola A.S., Myrmel K.S. Kloster R., Torp S.H., Lindal S., Unsgård G., et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. Jama. 2012;308(18):1881–8.

25. Tang S., Liao J., Long Y. Comparative assessment of the efficacy of gross total versus subtotal total resection in patients with glioma: A meta-analysis. International journal of surgery (London, England). 2019;63:90–7.

26. Li Y.M., Suki D., Hess K., Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? Journal of neurosurgery. 2016;124(4):977–88.

27. Avila E.K., Chamberlain M., Schiff D., Reijneveld J.C., Armstrong T.S., Ruda R., et al. Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-oncology. 2017;19(1):12–21.

28. Sugano H., Shimizu H., Sunaga S. Efficacy of intraoperative electrocorticography for assessing seizure outcomes in intractable epilepsy patients with temporal-lobe-mass lesions. Seizure. 2007;16(2):120–7.

29. Научный совет Министерства Здравоохранения РФ. Клинические рекомендации. Первичные опухоли центральной нервной системы. 2020:53.

30. Belhawi S.M., Hoefnagels F.W., Baaijen J.C., Aliaga E.S., Reijneveld J.C., Heimans J.J., et al. Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. European radiology. 2011;21(7):1526–34.

31. Karim A.B., Maat B., Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research andTreatment of Cancer (EORTC) Study 22844. International journal of radiation oncology, biology, physics. 1996;36(3):549–56.

32. Shaw E., Arusell R., Scheithauer B., O’Fallon J., O’Neill B., Dinapoli R., et al. Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2002;20(9):2267–76.

33. Malmström A., Grønberg B.H., Marosi C., Stupp R., Frappaz D., Schultz H., et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. The Lancet Oncology. 2012;13(9):916–26.

34. Loeffler J.S., Alexander E., 3rd, Shea W.M., Wen P.Y., Fine H.A., Kooy H.M., et al. Radiosurgery as part of the initial management of patients with malignant gliomas. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 1992;10(9):1379–85.

35. Baumert B.G., Lutterbach J., Bernays R., Davis J.B., Heppner F.L. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2003;67(2):183–90.

36. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009;10(5):459–66.

37. Трофимова Т.Н. Нейрорадиология: оценка эффективности хирургии и комбинированной терапии глиом. Практическая онкология. 2016;17(1):32–40.

38. Chung C., Bryant A., Brown P.D. Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery. The Cochrane database of systematic reviews. 2018;7(7): Cd011492.

39. Toyonaga T., Hirata K., Yamaguchi S., Hatanaka K.C., Yuzawa S., Manabe O., et al. (18) F-fluoromisonidazole positron emission tomography can predict pathological necrosis of brain tumors. European journal of nuclear medicine and molecular imaging. 2016;43(8):1469–76.

40. Park K.J., Kano H., Iyer A., Liu X., Niranjan A., Flickinger J.C., et al. Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case-control study. Journal of neuro-oncology. 2012;107(2):323–33.

41. Cabrera A.R., Cuneo K.C., Desjardins A., Sampson J.H., McSherry F., Herndon J.E., 2nd, et al. Concurrent stereotactic radiosurgery and bevacizumab in recurrent malignant gliomas: a prospective trial. International journal of radiation oncology, biology, physics. 2013;86(5):873–9.

42. Shepherd S.F., Laing R.W., Cosgrove V.P., Warrington A.P., Hines F., Ashley S.E., et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. International journal of radiation oncology, biology, physics. 1997;37(2):393–8.

43. Laing R.W., Warrington A.P., Graham J., Britton J., Hines F., Brada M. Efficacy and toxicity of fractionated stereotactic radiotherapy in the treatment of recurrent gliomas (phase I/II study). Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 1993;27(1):22–9.

44. Ney D.E. Carlson J.A., Damek D.M., Gaspar L.E., Kavanagh B.D., Kleinschmidt-DeMasters BK, et al. Phase II trial of hypofractionated intensity-modulated radiation therapy combined with temozolomide and bevacizumab for patients with newly diagnosed glioblastoma. Journal of neuro-oncology. 2015;122(1):135–43.

45. Kazda T., Dziacky A. Burkon P., Pospisil P., Slavik M.Rehak Z., et al. Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp’s Trial: More Controversies than Standards? Radiology and oncology. 2018;52(2):121–8.

46. Hanna C., Lawrie T.A., Rogozińska E., Kernohan A., Jefferies S., Bulbeck H., et al. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis. The Cochrane database of systematic reviews. 2020;3(3): Cd013261.

47. Кобяков Г.Л., Абсалямова О.В., Аникеева О.Ю., Бекяшев А.Х., Голанов А.В., Коновалов АН. Практические рекомендации по лекарственному лечению первичных опухолей центральной нервной cистемы. Злокачественные опухоли. 2015(4):55–79.

48. Nabors L.B., Portnow J., Ahluwalia M., Baehring J., Brem H., Brem S., et al. Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN. 2020;18(11):1537–70.

49. Weller M., van den Bent M., Tonn J.C., Stupp R., Preusser M., CohenJonathan-Moyal E., et al. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. The Lancet Oncology. 2017;18(6): e315-e29.

50. Broniscer A., Tatevossian R.G., Sabin N.D., Klimo P., Jr., Dalton J., Lee R., et al. Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma. Neuropathology and applied neurobiology. 2014;40(3):327–36.

51. Kleinschmidt-DeMasters B.K., Aisner D.L., Foreman N.K. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. The American journal of surgical pathology. 2015;39(4):528–40.